Aura Biosciences, Inc. is a clinical-stage biotechnology company. Co. is engaged in developing precision immunotherapies to treat solid tumors designed to preserve the function of the afflicted organ with cancer. It is developing a pipeline of virus-like drug conjugates (VDCs), a class of drugs with a dual mechanism of action, that promote cancer cell death by both the delivery of the cytotoxic payload to generate acute necrosis and activation of a secondary immune mediated response. The AURA stock yearly return is shown above.
The yearly return on the AURA stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2024 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the AURA annual return calculation with any dividends reinvested as applicable (on ex-dates).
|